Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
April W. Armstrong [1 ]
Ahmed M. Soliman [2 ]
Paolo Gisondi [3 ]
Siran Fang [2 ]
Manish Patel [2 ]
Bruce Strober [4 ]
机构：
[1] University of Southern California,Department of Dermatology, Keck School of Medicine
[2] AbbVie Inc.,Department of Medicine, Section of Dermatology and Venereology
[3] University of Verona,Department of Dermatology
[4] Yale University,undefined
[5] Central Connecticut Dermatology,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷 / 11期
关键词：
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab;
D O I：
10.1007/s13555-024-01293-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3071 / 3081
页数：10
相关论文
共 50 条
  • [1] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    April W. Armstrong
    Sang Hee Park
    Vardhaman Patel
    Malcolm Hogan
    Wei-Jhih Wang
    David Davidson
    Viktor Chirikov
    Dermatology and Therapy, 2023, 13 : 2589 - 2603
  • [2] Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
    April W. Armstrong
    Sang Hee Park
    Vardhaman Patel
    Malcolm Hogan
    Wei-Jhih Wang
    David Davidson
    Viktor Chirikov
    Dermatology and Therapy, 2023, 13 : 2605 - 2607
  • [3] MATCHING-ADJUSTED INDIRECT COMPARISON OF GUSELKUMAB VERSUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: CHANGE IN BASELINE PASI FROM WEEK 4-40
    Sanyal, C.
    Situ, A.
    Alulis, S.
    Hassan, F.
    Peterson, S.
    Lee, J.
    VALUE IN HEALTH, 2022, 25 (01) : S206 - S206
  • [4] COMPARATIVE EFFICACY OF GUSELKUMAB AND TILDRAKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Van, Sanden S.
    Diels, J.
    Schubert, A.
    Barthelmes, J.
    VALUE IN HEALTH, 2020, 23 : S410 - S410
  • [5] Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
    Langley, Richard G.
    Sanyal, Chiranjeev
    Situ, Aaron
    Alulis, Sarah
    Hassan, Fareen
    Peterson, Steve
    Teneralli, Rachel E.
    Lee, Jennifer
    Patel, Barkha P.
    Disher, Tim
    JAAD INTERNATIONAL, 2024, 15 : 165 - 167
  • [6] Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis
    Varu, Abhishek
    Cameron, Chris
    Diels, Joris
    Hutton, Brian
    McElligott, Sean
    Schubert, Agata
    van Sanden, Suzy
    Villacorta, Reggie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB187 - AB187
  • [7] Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
    Warren, R. B.
    Brnabic, A.
    Saure, D.
    Langley, R. G.
    See, K.
    Wu, J. J.
    Schacht, A.
    Mallbris, L.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1064 - 1071
  • [8] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis (vol 13, pg 2589, 2023)
    Armstrong, April W.
    Park, Sang Hee
    Patel, Vardhaman
    Hogan, Malcolm
    Wang, Wei-Jhih
    Davidson, David
    Chirikov, Viktor
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2605 - 2607
  • [9] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [10] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
12345